文献速递MDS 与骨髓增殖性肿瘤

西班牙骨髓纤维化注册研究中1613例骨髓纤维化患者血栓与出血的预测因素

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
PubMed 文献 · Br J Haematol · 2022-09-12

该研究基于西班牙骨髓纤维化注册研究1613例患者、共6981患者年随访,评估骨髓纤维化诊断后血栓与出血的发生率及危险因素;血栓发生率为1.65/100患者年,血栓史、JAK2突变及IPSS中危-2/高危增加血栓风险,抗凝治疗的中危-2/高危患者大出血风险近乎增加七倍。

要点

  • 骨髓纤维化诊断后血栓发生率为1.65/100患者年,至少一次血栓事件者占6.4%。
  • 血栓史、JAK2突变及IPSS中危-2/高危与血栓风险增加相关。
  • 抗凝治疗的中危-2/高危IPSS患者大出血风险近乎增加七倍。

核心结论

  • 血栓史、JAK2突变及IPSS中危-2/高危类别与骨髓纤维化诊断后血栓风险增加相关。
  • 抗凝治疗的中危-2/高危IPSS患者大出血风险近乎增加七倍。

研究设计与样本

  • 基于西班牙骨髓纤维化注册研究的1613例骨髓纤维化患者,共6981患者年随访。

主要发现

  • 诊断后至少一次血栓事件者占6.4%,发生率为1.65/100患者年。
  • 血栓史、JAK2突变及IPSS中危-2/高危类别在调整抗血栓及细胞减灭治疗影响后仍与血栓风险增加相关。
  • 血栓史与JAK2突变可识别早期血栓高风险患者。
  • 抗血栓或细胞减灭治疗期间未观察到血栓发生率下降。
  • 免疫调节剂治疗期间静脉血栓风险增加。

关键数值与推荐

  • 血栓发生率1.65/100患者年,至少一次血栓事件者占6.4%。
  • 大出血发生率1.5/100患者年,至少一次大出血事件者占5.3%。

临床怎么用

  • 作者认为这些发现有助于指导临床实践中的决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated the incidence and risk factors of vascular complications in 1613 patients from the Spanish Myelofibrosis Registry. Over a total of 6981 patient-years at risk, 6.4% of the study population had at least one thrombotic event after MF diagnosis, amounting to an incidence rate of 1.65 per 100 patient-years. Prior history of thrombosis, the JAK2 mutation, and the intermediate-2/high-risk International Prognostic Scoring System (IPSS) categories conferred an increased thrombotic risk after adjustment for the risk-modifying effect of anti-thrombotic and cytoreductive treatments. History of thrombosis and the JAK2 mutation allowed us to pinpoint a group of patients at higher risk of early thrombosis. No decreased incidence of thrombosis was observed while patients were on anti-thrombotic or cytoreductive treatment. An increased risk of venous thrombosis was found during treatment with immunomodulatory agents. A total of 5.3% of patients had at least one episode of major bleeding, resulting in an incidence rate of 1.5 events per 100 patient-years. Patients in the intermediate-2/high-risk IPSS categories treated with anti-coagulants had an almost sevenfold increased risk of major bleeding. These findings should prove useful for guiding decision-making in clinical practice.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hernández-Boluda JC, Pastor-Galán I, Arellano-Rodrigo E, et al. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. Br J Haematol. 2022. PMID: 36089912. doi:10.1111/bjh.18440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。